\n<\/p>\n
Successful <\/b>Turnaround to Profit-making with Record-High Turnover<\/b><\/p>\n
\n
<\/p>\n
Expanding
\nR&D Activity in <\/b>Nanobody Drug to
\nDiversify Product Portfolio<\/b><\/p>\n
\n
<\/p>\n
HONG KONG SAR
\u00a0<\/p>\n
Key Accomplishments in the First Half of 2021<\/b><\/p>\n
During the Period,
\u00a0<\/b><\/p>\n
1.\u00a0\u00a0\u00a0 Coupled with its ongoing cost control
\u00a0<\/b><\/p>\n
2.\u00a0\u00a0\u00a0 On 3 February 2021, the Group’s Pinup\u00ae<\/sup>
3.\u00a0\u00a0\u00a0
4.\u00a0\u00a0\u00a0 Boshutai\u00ae was officially approved for
\u00a0<\/p>\n
5.\u00a0\u00a0\u00a0 During the Period, the Group was in
\u00a0<\/p>\n
6.\u00a0\u00a0\u00a0 The Group has been preparing for the
\u00a0<\/p>\n
7.\u00a0\u00a0\u00a0 During the Period, the Group developed
\u00a0<\/b><\/p>\n
Interim
During the Period, the Group
\u00a0<\/p>\n
Gross profit was HK$124.4 million, representing an increase of 117.1% as
\u00a0<\/p>\n
For the Period, the Group recorded a profit of HK$1.9 million with a
\u00a0<\/p>\n
Prospects<\/b><\/p>\n
China’s healthcare industry has been growing rapidly over the past few
\u00a0<\/b><\/p>\n
As the Group’s exclusive distribution and promotion rights of GeneSoft\u00ae
\u00a0<\/p>\n
Looking into the future, Mr. Kingsley Leung, Chairman of Uni-Bio Science<\/b> said, ” This was the
Successful Turnaround to Profit-making with Record-High Turnover
Expanding
R&D Activity in Nanobody Drug to
Diversify Product Portfolio
HONG KONG SAR
–\u00a0EQS Newswire\u00a0– 27 August 2021\u00a0– A fully integrated biopharmaceutical company \u2013 Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its
subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17228"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=17228"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17228\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=17228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=17228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=17228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n–\u00a0EQS Newswire\u00a0– 27 August 2021\u00a0– A fully integrated biopharmaceutical company \u2013 Uni-Bio Science Group Limited<\/a><\/b> (“Uni-Bio Science”, together with its
\nsubsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for six months ended 30 June 2021 (the “Period”), as well as its comparative figures for six months ended 30 June 2020.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nthe Group achieved a spectrum of accomplishments, for both of its marketed
\nproducts and innovative biologics. The key highlights include:<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nmeasures, the Group achieved a profit for the Period of HK$1.9 million as
\ncompared with a loss of HK$11.5 million for the corresponding period of last
\nyear. This is the first time that the Group has recorded profit solely from its
\ncore business operations. It signifies that the Group has started yielding
\nfruits and has entered the path of sustainable profit growth.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n(Voriconazole Tablets 50mg) was the first one to be selected among the same
\ncategory in the Fourth Batch of the National Centralized Procurement. After
\nbeing included in the volume-based procurement, Pinup\u00ae<\/sup> recorded a
\nnoticeable increase of 257.3% YoY in turnover from approximately HK$15.7
\nmillion to approximately HK$56.1million during the Period. Market access,
\nespecially hospital listing, had always been the biggest challenge to Pinup\u00ae<\/sup>.
\nAfter being included in the volume-based procurement, Pinup\u00ae<\/sup> is in a
\ngreat position to quickly penetrate into the public hospital markets. Moreover,
\nbeing listed in the national volume-based procurement is the local regulator’s
\npush to reduce intermediaries in the sales channel, further enhancing the
\nefficiency and reducing the cost of the healthcare industry in China. <\/p>\n
\n
<\/p>\n
\nDuring
\nthe Period, GeneTime\u00ae and GeneSoft\u00ae generated remarkable turnover, sales of
\nGeneTime\u00ae and GeneSoft\u00ae registered significant increase of 116.8% YoY and 45.8%
\nYoY respectively.The sales of GeneTime\u00ae exceeded the pre-epidemic level and the
\ndemand for the product was far beyond the supply during the first half of 2021.<\/span><\/p>\n
\n
\n
\n
<\/p>\n
\nmarketing in China by the National Medical Products Administration (“NMPA”)
\nand being qualified for GMP manufacturing in 2020, the Group had started the
\nproduction of Boshutai\u00ae in the first quarter of 2021 and the sales of Boshutai\u00ae
\nhad made immediate contribution to the Group during the Period.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\npreparation for the bridging clinical trial for 2nd Generation liquid form
\nUni-PTH as planned. The clinical trial will be officially launched in August
\n2021 and is expected to be finished by the end of 2021, following by a New Drug
\nApplication (“NDA”) in 2022. <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nclinical trial-related works for Uni-GLP, which is expected to carry out in the
\nthird quarter of 2021. The Group has been in constant communications with the
\nNMPA regarding the optimization of the bridging clinical trials. If the results
\nare satisfying, phase III of the clinical trials may not be needed and this
\nwill accelerate the approval process of Uni-GLP.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nstrategic partnership with DotBio Pte. Ltd. (“DotBio”) to co-develop
\nmulti-specific nanobodies for people with retinal diseases. Leveraging on
\nDotBio’s unparalleled technology capability in the ophthalmology space,
\ntogether with the Group’s extensive experience in fermentation, purification,
\nquality assurance and quality control of E.coli-expressed proteins, this
\npartnership is able to diversify the Group’s pipeline and capture the rising
\nneeds of the age-related macular degeneration (AMD) treatment market.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nResults<\/b><\/p>\n
\n
<\/p>\n
\nrecorded a turnover of HK$ 157.0 million, representing a noticeable increase of
\napproximately 132.8% year-on-year (first half of 2020: HK$ 67.4 million). The
\nincrease in turnover was mainly attributable to the strong rebounded sales of
\nthe Group’s core products after the effective pandemic control of COVID-19 in
\nChina and the resumption of hospital services. Turnover generated from
\nGeneTime\u00ae reached HK$82.4 million, representing a significant increase of
\n116.8% from approximately HK$38 million in first half of 2020, mainly due to
\nthe strong recovery from hospital sales as well as the additional turnover from
\nthe digital marketing and pharmaceutical e-commerce platform. Sales of GeneSoft\u00ae<\/sup>
\nhad been fully recovered during the Period, recorded an increase in turnover
\nfrom approximately HK$11.8 million to HK$17.2 million. Pinup\u00ae <\/sup>has
\nrecorded a noticeable increase of 257.3% in turnover from approximately HK$15.7
\nmillion to approximately HK$56.1million during the Period. Turnover of the
\nGroup’s newly launched product Boshutai\u00ae <\/sup>(Acarbose tablet) was
\napproximately HK$1.3 million.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\ncompared with approximately HK$57.3 million for the first half 2020. \u00a0Gross
\nprofit margin was at 79.3% (first half of 2020: 85.0%) as the pricing of Pinup\u00ae<\/sup>
\nfor the centralized procurement was significantly lower but was partly offset
\nby the economies of scale from mass production volume. The Group continued its
\nstrict control in general and administrative expenses, which only accounted for
\n14.2% of turnover for the Period as compared with 29.0% for the same period
\nlast year. The selling and distribution expense for the Period also decreased
\nto 48.5% of turnover from 63.1% that of the same period last year due to the
\nGroup’s further optimization of its direct salesforce. The R&D expenses
\nincreased by 164.6% to HK$21.4 million and the amount was in step with the
\nGroup’s product research status. <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nbasic earnings per share of HK$0.03 cents, registering a turnaround from a loss
\nof HK$11.5 million or a basic loss per share of HK$0.18 cents in the first half
\nof 2020. This was the first half-year that the Group achieved a profit from
\noperations, which marked the beginning of yielding fruits of the Group’s
\nbiopharmaceutical investment and efforts over the past years.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nyears and has become the second biggest in the world since 2016. The growth is
\nnot only driven by the aging population, which leads to an increasing number of
\npeople diagnosed with chronic diseases, but also with the support of government
\npolicies. As one of the innovative pharmaceutical companies in China, the Group
\nbelieves that these catalysts will drive greater business growth in the future.
\n<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nwith its partners, CR Zizhu, came to an end in June 2021, the Group has started
\nleveraging its well-established direct sales team to promote GeneSoft\u00ae in
\nmultiple channels. With shared resources with GeneTime\u00ae, the sales as well as
\nthe profitability are expected to significantly improve going forward. To
\naddress the unmet need of medical aesthetic, the Group is in discussion with
\nvarious potential partners to explore innovative formulations of EGF products.
\nLeveraging on its innovative material technology, the Group is able to
\ndiversify the formulation of EGF products and potentially expand its
\napplication scope.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nfirst half-year that the Group achieved a profit solely from its core
\noperations. It also marked the beginning of profit-making of the Group’s biopharmaceutical
\ninvestment and efforts over the past years as it is expected to enter the path of sustainable profit growth. In order to expand the product capacity to
\nmeet the growing demands of GeneSoft\u00ae and GeneTime\u00ae, we decided to relocate the
\nproduction site to Dongguan. The new production base will be equipped with new
\ntechnology that would further reduce production and transportation costs as
\nwell as overheads while enhancing the overall production capacity. To explore
\nnew business opportunities in ophthalmology field, the Group is cooperating with
\nDotbio and potential partners to develop potential best-in-class therapeutic
\nproducts that can compete in a global setting. To capture more value in the
\ndermatology space, we may also develop a third molecule with Dotbio. The Group
\nwill also continue to focus on the research and development of the innovative
\ndrugs, including Uni-PTH and Uni-GLP. We believe that aforementioned strategies
\nwill enhance operational efficiency, accelerate product pipelines and sustain
\nits growth momentum. These would in turn generate more fruitful returns for its
\nshareholders.”<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"